
Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Study: New breeding methods hardly contribute to climate protection
Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...

Spain set to unveil the potential of the biologisation of medicine and food production
At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

Novo Nordisk invests €2.1bn in production expansion
While Novo Nordisk’s main competitor Eli Lilly in the emerging market of effective drugs that fight obesity announced an investment of €11bn...